Get started
Author

Angelo Camporeale

Observed names: A Camporeale, Camporeale, Angelo
Institution: Eli Lilly (Italy)
OpenAlex ID: A5103916690
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention
2017 · Vladimir Skljarevski, Tina M. Oakes, et al. · JAMA Neurology · 172
PDF
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
2018 · Angelo Camporeale, David Kudrow, et al. · BMC Neurology · 136
PDF
Use of calcitonin in the treatment of bone pain associated with osteoporosis
1991 · Carlo Gennari, Donato Agnusdei, et al. · Calcified Tissue International · 94
Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
2018 · Tina Marie Myers Oakes, Vladimir Skljarevski, et al. · Cephalalgia · 49
Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1, EVOLVE‐2, and REGAIN Studies
2019 · Tina M. Oakes, Richard Kovacs, et al. · Headache The Journal of Head and Face Pain · 47
Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: a placebo-controlled, randomised withdrawal study
2013 · Himanshu Upadhyaya, J. Antoni Ramos-Quiroga, et al. · The European Journal of Psychiatry · 31
PDF
Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: An integrated analysis of 15 clinical trials
2014 · Angelo Camporeale, Vibeke Porsdal, et al. · Journal of Psychopharmacology · 29
Profile of Sexual and Genitourinary Treatment-Emergent Adverse Events Associated with Atomoxetine Treatment: A Pooled Analysis
2013 · Angelo Camporeale, Kathleen Ann Day, et al. · Drug Safety · 27
Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
2020 · Virginia L. Stauffer, Ira Turner, et al. · The Journal of Headache and Pain · 20
PDF
Safety and tolerability of atomoxetine hydrochloride in a long-term, placebo-controlled randomized withdrawal study in European and non-European adults with attention-deficit/hyperactivity disorder
2013 · Angelo Camporeale, Himanshu Upadhyaya, et al. · The European Journal of Psychiatry · 15
PDF
Efficacy and Safety Extrapolation Analyses for Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder
2014 · Himanshu Upadhyaya, Christopher Kratochvil, et al. · Journal of Child and Adolescent Psychopharmacology · 10
Management of Osteoporosis and Paget??s Disease
1994 · Carlo Gennari, Ranuccio Nuti, et al. · Drug Safety · 9
Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine
2020 · Virginia L. Stauffer, Shufang Wang, et al. · BMC Neurology · 7
PDF
Effect of rectal salmon calcitonin treatment on bone mass and bone turnover in patients with established postmenopausal osteoporosis: A 1-year crossover study
1993 · Stefano Gonnelli, Donato Agnusdei, et al. · Current Therapeutic Research · 4
Evaluation of Cardiovascular Risks in Adult Patients with Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies (P1.10-010)
2019 · Tina Oakes, Richard Kovacs, et al. · Neurology · 2
Hepatic safety of galcanezumab in patients with migraine: Results of three Phase 2 double-blind placebo-controlled trials (P2.164)
2017 · Arie Regev, Angelo Camporeale, et al. · Neurology · 2
Paget bone disease and heredity: a case report.
1988 · D Agnusdei, R Civitelli, et al. · PubMed · 1
Long-term Treatment with Galcanezumab in 29 Patients with Chronic Migraine: Results from the 3-year Continued Access Program of the REGAIN Study (P1-1.Virtual)
2022 · Amnon Mosek, Lily Q. Li, et al. · Neurology
Evaluation of Cardiovascular Risks in Patients Treated With Longer-term Exposure to Galcanezumab (2344)
2021 · Tina Oakes, Richard Kovacs, et al. · Neurology
Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
2021 · Virginia L. Stauffer, Tina M. Oakes, et al. · Journal of Neurology
PDF
Effect of Age on Efficacy and Safety of Galcanezumab Treatment in Adult Patients with Migraine (P2.10-021)
2019 · Virginia L. Stauffer, Ira Turner, et al. · Neurology
Works count: 23
Citation count: 655
H-index: 10
I10-index: 11
Year
Topic
Type